Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.59 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.58 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.58 |
| ▸ | TUBB4A | P04350 | 4/20 | 0.58 |
| ▸ | TUBB | P07437 | 4/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 4/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 4/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 4/20 | 0.58 |
| ▸ | TUBB4B | P68371 | 4/20 | 0.58 |
| ▸ | TUBB3 | Q13509 | 4/20 | 0.58 |
| ▸ | TUBB2A | Q13885 | 4/20 | 0.58 |
| ▸ | TUBB8 | Q3ZCM7 | 4/20 | 0.58 |
| ▸ | TUBA3E | Q6PEY2 | 4/20 | 0.58 |
| ▸ | TUBA1A | Q71U36 | 4/20 | 0.58 |
| ▸ | TUBA1C | Q9BQE3 | 4/20 | 0.58 |
| ▸ | TUBB6 | Q9BUF5 | 4/20 | 0.58 |
| ▸ | TUBB2B | Q9BVA1 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6286253 | 0.87 | TUBB1 (0.58) | HDAC6HDAC3HDAC1PAX8TUBB1 | |
| SCHEMBL6286224 | 0.84 | PAX8 (0.68) | HDAC6HDAC3HDAC1PAX8TUBB1 | |
| SCHEMBL17288342 | 0.84 | PAX8 (0.81) | PAX8TUBB1TUBB4ATUBBTUBA3C | |
| SCHEMBL25662539 | 0.83 | HDAC6 (0.80) | HDAC6HDAC3HDAC1TUBB1TUBB4A | |
| SCHEMBL5840582 | 0.82 | PAX8 (0.62) | HDAC6HDAC3HDAC1PAX8TUBB1 | |
| SCHEMBL13622220 | 0.80 | PAX8 (0.62) | HDAC6HDAC3HDAC1PAX8TUBB1 | |
| SCHEMBL6283753 | 0.79 | HDAC6 (0.63) | HDAC6HDAC3HDAC1PAX8TUBB1 | |
| SCHEMBL14117852 | 0.79 | HDAC6 (0.78) | HDAC6HDAC3HDAC1TUBB1TUBB4A | |
| SCHEMBL6893117 | 0.79 | HDAC6 (0.62) | HDAC6HDAC3HDAC1PAX8TUBB1 | |
| SCHEMBL14480682 | 0.79 | HDAC6 (0.75) | HDAC6HDAC3HDAC1TUBB1TUBB4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6846925-B2 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | claimed |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED | 2004-07-22 | — | — | US | claimed |
| US-6720323-B2 | N-((5S)-3,9,10,11-TETRAMETHOXY-6,7-DIHYDRO-5H-DIBENZO(A,C) CYCLOHEPTEN-5-YL)-2-(2-AMINOACETYLAMINO)ACETAMIDE; DESTROYS NEWLY FORMED VASCULATURE WHILE LEAVING UNAFFECTED NORMAL, MATURE VASCULATURE. | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2004-04-13 | — | — | US | claimed |
| JP-2004504391-A | — | — | 2004-02-12 | — | — | JP | claimed |
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2003-10-16 | — | — | US | claimed |
| EP-1301498-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | Angiogene Pharmaceuticals Limited (GB) | 2003-04-16 | — | — | EP | claimed |
| WO-2002008213-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2002-01-31 | — | — | WO | claimed |
| US-6846925-B2 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2005-01-25 | — | — | US | disclosed |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED | 2004-07-22 | — | — | US | disclosed |
| US-6720323-B2 | N-((5S)-3,9,10,11-TETRAMETHOXY-6,7-DIHYDRO-5H-DIBENZO(A,C) CYCLOHEPTEN-5-YL)-2-(2-AMINOACETYLAMINO)ACETAMIDE; DESTROYS NEWLY FORMED VASCULATURE WHILE LEAVING UNAFFECTED NORMAL, MATURE VASCULATURE. | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2004-04-13 | — | — | US | disclosed |
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| EP-1301498-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | Angiogene Pharmaceuticals Limited (GB) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002008213-A1 | COLCHINOL DERIVATIVES AS ANGIOGENESIS INHIBITORS | ANGIOGENE PHARMACEUTICALS LIMITED (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195173-A1 | Colchinol derivatives as angiogenesis inhibitors | FLT1, CCNO, FLT4 | HDAC6 900/4885HDAC3 270/4885HDAC1 416/4885 |
| US-20040142909-A1 | Colchinol derivatives as angiogenesis inhibitors | FLT1, CCNO, FLT4 | HDAC6 920/4885HDAC3 269/4885HDAC1 421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.